Results 161 to 170 of about 146,080 (258)

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami   +6 more
wiley   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui   +15 more
wiley   +1 more source

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Balinatunfib is the first oral, small molecule selective inhibitor of TNFR1 signaling. The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe adverse events in patients with mild‐to‐moderate psoriasis and showed clinical responses.
Nassr Nassr   +10 more
wiley   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault   +51 more
wiley   +1 more source

Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study. [PDF]

open access: yesRMD Open
Nikoloudaki M   +15 more
europepmc   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth   +8 more
wiley   +1 more source

Inverted T‐Shape Connective Tissue Graft for Interdental Papilla Reconstruction: A Clinical Case Series

open access: yesJournal of Esthetic and Restorative Dentistry, EarlyView.
ABSTRACT Objective To evaluate the clinical application and outcomes of the inverted T‐shape connective tissue graft (IT‐CTG) technique for reconstructing deficient interdental papillae in cases of advanced gingival recession, focusing on both quantitative and qualitative results in a consecutive case series.
Abdusalam E. Alrmali   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy